MedTrace Logo

Rivaroxaban for Intracardiac Thrombosis in the Pediatric Population

NCT06371170 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-04-19

No results posted yet for this study

Summary

The goal of this observational study is to determine the efficacy of rivaroxaban treatment for intracardiac thrombi resolution in pediatric patients (\< 16 years old) diagnosed with intracardiac thrombosis. The main question it aims to answer is: Does rivaroxaban treatment resolve the thrombosis during a 3-month treatment?

Participants already taking rivaroxaban as part of their regular medical care for thrombosis resolution. They will undergo monthly visits to check that the treatment is progressing correctly and that no major bleeding has occurred. After 3 months of treatment, they will repeat the radiological imaging investigation to verify the actual resolution of the thrombosis.

Conditions

  • Intracardiac Thrombus

Interventions

DRUG

Rivaroxaban

Oral anticoagulation

Sponsors & Collaborators

  • Azienda Ospedaliero, Universitaria Ospedali Riuniti

    lead OTHER

Principal Investigators

  • Francesco Bianco, M.D., Ph.D. · AOU - Ospedali Riuniti Ancona

Eligibility

Min Age
1 Month
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2025-01-01
Completion
2027-01-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06371170 on ClinicalTrials.gov